MII IG Medikation
2027.0.0-ballot -
Germany
This page is part of the MII Implementation Guide MII IG Medikation (v2027.0.0-ballot: 2027 Ballot 2) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
This page was newly written during the migration. The Simplifier guide had no guidance for researchers; the text draws together statements from the module description, the terminology page and the context chapter for this audience. Needs domain review.
Anyone analysing medication data soon notices that the same therapy can look very different in the data. That is not a modelling error but deliberate: sites document at different levels of detail, and the module represents that range on purpose. For queries it means that searching on one pattern alone will systematically miss cases.
A medication can be coded at three levels, and all three are permitted:
Practical consequence: searching for "all patients on bisoprolol" finds, via the PZN, only those cases where a product was recorded, and via the ATC code also combination products that contain more than what was sought. A defensible cohort usually emerges only from combining several routes.
There is also the distinction between precise and general ingredient: "bisoprolol hemifumarate" and "bisoprolol" are not the same, and their quantities differ — 10 mg of the salt corresponds to 8.49 mg of the pure substance. Which level is present is stated by the Wirkstofftyp extension; Wirkstoffrelation establishes the mapping between the two. Aggregating doses without accounting for this adds up unlike things.
A Medication references further Medication resources through ingredient.itemReference. This is needed in two places:
For analyses this means: a single Medication is not necessarily the whole story. Counting ingredients without following the reference chain loses, for combination packages, exactly the information being sought — the ingredient sits one level down.
Three resources appear to describe something similar but mean different things:
A question about exposure is answered by the administration, a question about therapeutic intent by the order. Conflating the two overestimates exposure.
The module requires the active ingredient as a minimum. Trade name, dose with unit, dosage regimen, dose form as well as site and route of administration are provided for but not present everywhere — the share of structured medication documentation differs considerably between sites. For multi-centre analyses it is advisable to check completeness per site beforehand rather than assume it.
Which code systems apply where is described under Terminologies; an overview of the data elements is under Datasets and descriptions.